Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jhasketan Meher

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Infection in Developing Countries|August 14, 2014
Dengue encephalopathy - still an enigma?Rupali Malik, Arun Gogna, Jhasketan Meher, et al.
Drug Target Insights|June 11, 2024
RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patientsDablu Lal Gupta, Jhasketan Meher, Anjan Kumar Giri, et al.
Clinical Therapeutics|May 18, 2025
Analysis of the Total Immunoglobulin G (IgG) and Its Subclasses Over Time in Coronavirus Disease 2019-Recovered Patients and Its Association With Disease Severity: A Single-Center Prospective Cohort StudyDablu Lal Gupta, Jhasketan Meher, Fagun Sharma, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Infection in Developing Countries|August 14, 2014
Dengue encephalopathy - still an enigma?Rupali Malik, Arun Gogna, Jhasketan Meher, et al.
Drug Target Insights|June 11, 2024
RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patientsDablu Lal Gupta, Jhasketan Meher, Anjan Kumar Giri, et al.
Clinical Therapeutics|May 18, 2025
Analysis of the Total Immunoglobulin G (IgG) and Its Subclasses Over Time in Coronavirus Disease 2019-Recovered Patients and Its Association With Disease Severity: A Single-Center Prospective Cohort StudyDablu Lal Gupta, Jhasketan Meher, Fagun Sharma, et al.
Pageof 1